Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
This study proposes to prove that the efficacy of adjuvant endocrine therapy for the premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy assessed by ultrasound response rate.
Breast Cancer
DRUG: Goserelin+TAM+AI|DRUG: Epirubicin+CTX+5-Fu
ultrasound response rate, within 2 weeks before surgery
pathological response rate(Miller & Payne standard), with 2 weeks after surgery
This study proposes to prove that the efficacy of adjuvant endocrine therapy for the premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy assessed by ultrasound response rate.